After a two-year follow-up, patients who improved their adherence to the MedDiet experienced reductions in systemic inflammation, IFC, the FLI, and plasma levels of CK-18, a key biomarker in the progression of fatty liver disease. This evidence concerns the gene KRT18 and fatty liver disease.